Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

NCT05763927 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Fruquintinib
DRUG: Toripalimab
RADIATION: Short-course radiotherapy
PROCEDURE: TME

Sponsor

West China Hospital